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Abstract
Background: Cockroach allergy is strongly associated with asthma, and involves the production of IgE antibodies against
inhaled allergens. Reports of conformational epitopes on inhaled allergens are limited. The conformational epitopes for two
specific monoclonal antibodies (mAb) that interfere with IgE antibody binding were identified by X-ray crystallography on
opposite sites of the quasi-symmetrical cockroach allergen Bla g 2.
Methodology/Principal Findings: Mutational analysis of selected residues in both epitopes was performed based on the X-
ray crystal structures of the allergen with mAb Fab/Fab9 fragments, to investigate the structural basis of allergen-antibody
interactions. The epitopes of Bla g 2 for the mAb 7C11 or 4C3 were mutated, and the mutants were analyzed by SDS-PAGE,
circular dichroism, and/or mass spectrometry. Mutants were tested for mAb and IgE antibody binding by ELISA and
fluorescent multiplex array. Single or multiple mutations of five residues from both epitopes resulted in almost complete
loss of mAb binding, without affecting the overall folding of the allergen. Preventing glycosylation by mutation N268Q
reduced IgE binding, indicating a role of carbohydrates in the interaction. Cation-p interactions, as well as electrostatic and
hydrophobic interactions, were important for mAb and IgE antibody binding. Quantitative differences in the effects of
mutations on IgE antibody binding were observed, suggesting heterogeneity in epitope recognition among cockroach
allergic patients.
Conclusions/Significance: Analysis by site-directed mutagenesis of epitopes identified by X-ray crystallography revealed an
overlap between monoclonal and IgE antibody binding sites and provided insight into the B cell repertoire to Bla g 2 and
the mechanisms of allergen-antibody recognition, including involvement of carbohydrates.
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Introduction
Exposure and sensitization to cockroach is associated with the
development of asthma, and up to 81% of children in inner-city
areas of the U.S. are sensitized to cockroach allergens [1–3].
Among such allergens, Bla g 2 is of particular importance, eliciting
IgE responses in 58–70% of cockroach allergic patients [4–6]. The
X-ray crystal structure of Bla g 2 shows a bilobal fold typical of
pepsin-like aspartic proteases, but Bla g 2 is enzymatically inactive
due to amino acid substitutions in the catalytic site [7,8]. The
structures of both lobes are similar despite the low degree of the
amino acid sequence homology (,15% identity) [9]. The presence
of a zinc binding site and five disulfide bridges in Bla g 2 adds
stability to the protein, thus favoring persistence of the allergen in
the environment [7]. Chronic exposure to low doses (,1 mg/g
dust) of this stable cockroach allergen may explain the association
between sensitization to Bla g 2 and asthma [3,6].
Most reports on epitope mapping of allergens focus on the
identification of linear epitopes by using libraries of overlapping
synthetic peptides, recombinant fragments of the allergen, epitope
expression cDNA libraries, or digested allergens. These approach-
es are especially useful for food allergens where linear epitopes are
common due to allergen digestion (in addition to conformational
epitopes) [10,11]. However, conformational IgE antibody binding
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respiratory system mostly in their original globular structure. Little
is known about the IgE antibody binding repertoire, the clonality
and affinity of the interactions, the location and structure of
epitopes and the kind of interactions involved in antibody
recognition of the allergen [12–15]. Our aim was to map
conformational antigenic determinants of Bla g 2 using the
tertiary structure of the molecule as a ‘‘template’’ for mutagenesis,
and to analyze the effect of amino acid substitutions on mAb and
IgE antibody binding in order to gain insight on the IgE antibody
binding repertoire. The epitope mapping approach presented here
was based on the determination of the molecular structure of two
allergen-antibody complexes by X-ray crystallography, which
provided an accurate molecular structure of the conformational
epitopes. Subsequently, site-directed mutagenesis was performed
to confirm that the amino acids found at the interfaces are essential
for antibody binding. For mapping B cell epitopes, it is not feasible
to co-crystallize IgE antibodies with the allergen, due to the
polyclonal nature of IgE and its paucity in sera (,1 mg/ml
compared with approximately 10 mg/ml for IgG). Therefore,
mAb 7C11 and 4C3 which interfere with the binding of IgE
antibodies, were selected to facilitate the identification of residues
and kinds of interactions involved in such binding.
Fragments of the non-overlapping mAb 7C11 and 4C3, raised
against natural Bla g 2, were independently co-crystallized with
recombinant Bla g 2 (rBla g 2) and the structures were determined
[16,17]. Subsequent site-directed mutagenesis of the residues
involved in the mAb epitopes led to the identification of amino
acids that are important for the allergen-mAb interaction.
Additionally, amino acids involved in IgE binding were identified,
indicating an overlap of epitopes for IgE and monoclonal antibodies.
Materials and Methods
Sera from cockroach allergic patients
Sera from cockroach allergic patients were obtained from
commercial sources (Bioreclamation, Inc., Westbury, NY) or from
stored samples that had been collected from patients enrolled in
1988–1989 in Wilmington (Delaware) and Charlottesville (Virginia)
for epidemiological studies performed at the University of Virginia
[18,19]. Bioreclamation operates in full compliance with Food and
Drug Administration guidelines. The studies performed at the
University of Virginia were approved by the Human Investigation
Committee and blood was drawn after informed written consent
was obtained from the patient. IgE antibody levels in sera ranged
from 7 to 640 ng of total IgE/ml (average 1476177 ng/ml) [18]
and 0.4–100 ng of IgE against Bla g 2/ml (average 41627 ng/ml),
measured by mAb-based RIA [4]. A pool of 6 sera from cockroach
allergic patients highly sensitized to Bla g 2 was used for inhibition
assays. The pool contained 18.6 kUA/L of cockroach extract-
specific IgE (i6) and 4.2 kUA/L of Bla g 2-specific IgE by
ImmunoCAP (Phadia AB, Uppsala, Sweden) measured by using
streptavidin CAPs coated with biotinylated Bla g 2.
Rational design of mutagenesis
Rational design of site-directed mutagenesis was based on the
crystal structures of Bla g 2 alone and in complex with the
fragments of the mAb 7C11 and 4C3 (PDB accession codes 1yg9,
2nr6 and 3liz, respectively) [7,16,17]. Structural images were
created with the program PyMol [20].
Site-directed-mutagenesis
Five rBla g 2 mutants, each containing a single amino acid
substitution within the 7C11 binding epitope (K65A, D68aA,
R83A, E86A, and K132A), as well as eight mutants of the epitope
for the mAb 4C3 (E233A, D248A, K251A, E233R, and E233R-
I199W on N93Q; E233R and E233R-I199W on N268Q, and
N268Q alone) were designed. The mutations E233A, D248A,
K251A, E233R, and E233R-I199W were performed on the rBla g
2-N93Q mutant which is the molecule that had been crystallized
(alone and in complex with mAb fragments) and served as the
basis for the mutational analysis. The N93Q substitution, distant
from the mAb epitopes, had been introduced in order to prevent
glycosylation of Bla g 2, which interferes with crystallization. Thus
the rBla g 2-N93Q was considered to contain the intact mAb
epitopes. In addition, mutants E233R and E233R-I199W with a
N268Q mutation (instead of N93Q), and the N268Q mutation
alone, were also designed. The Bla g 2-DNA was inserted into the
yeast P. pastoris expression vector pGAPZaC for constitutive
expression of the allergen. Site-directed mutagenesis was per-
formed using QuikChange
TM (Stratagene). Sequence of the
mutated DNA was confirmed before linearization and transfor-
mation into the P. pastoris strain KM71.
Expression, purification, and analysis of Bla g 2 mutants
in Pichia pastoris
Expression of recombinant proteins in P. pastoris was performed
as described [8]. Recombinant Bla g 2-N93Q (with intact epitopes
for 7C11 and 4C3 mAbs), rBla g 2-N268Q, and epitope mutants
were purified from culture media by affinity chromatography
using either mAb 7C11 or 4C3. Both monoclonals had been
produced against natural Bla g 2, and recognize both natural and
the recombinant allergen. Parallel dose-response curves were
observed for both recombinant and natural Bla g 2 by two-side
mAb binding ELISAs using combinations of 7C11 and 4C3 mAb.
Analysis of recombinant mutants by circular dichroism (CD) and
mass spectrometry was performed as follows. The far UV CD
spectra were recorded at concentrations around 0.1 mg/ml upon
addition of 10 mM sodium phosphate pH 7.4 between 190 and
260 nm, using a Jasco J-810 spectropolarimeter (Japan Spectro-
scopic), temperature-controlled at 20uC. NanoLC-MSMS-based
peptide mapping (CapLC, Micromass-Waters) of proteolytic digests
was performed using trypsin and V8 protease (Roche). For the
R83A mutant, additional digests were mapped with subtilisin and
pepsin (Sigma-Aldrich). MSMS data were evaluated automatically
using PLGS 2.2.5
TM software. An in house allergen sequence
databank was used for MSMS data search in nonspecific digestion
mode with carbamidomethylation set as fixed modification.
Inhibition of IgE antibody binding by mAb 7C11
Microplates were coated with 20 mg/ml rBla g 2-N93Q in
50 mM carbonate-bicarbonate buffer, pH 9.6. The antibodies
tested for inhibition of IgE antibody binding were the anti-Bla g 2
mAb 7C11 (at 0, 0.001, 0.01, 0.1, 1 and 10 mg/ml concentrations),
and a rabbit polyclonal anti-Bla g 2 antibody (at 1:10 dilutions).
These antibodies were added, followed by addition of sera from
cockroach allergic patients with high anti-Bla g 2 IgE antibody
titer (1:4 or 1:10 final dilution). Incubation was performed at room
temperature for 2 h. Affinity purified peroxidase labeled goat anti-
human antibody IgE (Kirkegaard and Perry Laboratories) was
used for detection at 1:1000. Plates were developed as previously
described [21].
ELISA to measure rBla g 2 mutants and dose-response
curves of epitope mutants
Recombinant Bla g 2 was measured by ELISA using either the
mAb 7C11 or 4C3 as capture antibody and a Bla g 2-specific
Mechanisms of Antibody Binding to Bla g 2
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containing natural Bla g 2 was used starting at 250 ng/ml.
The epitope mutants and rBla g 2-N93Q were compared by
performing dose-response experiments using mAb 7C11 or 4C3 as
capture antibodies and biotinylated mAb 4C3 or 7C11 for
detection, respectively, or polyclonal antibody. The biotinylated
and polyclonal antibodies used for capture were first titrated in
order to select the concentration to be used in the dose-response
experiments. This concentration was the lowest possible, closest to
the Kd of the allergen-antibody interaction (nM range for mAb
7C11 and 4C3; 8 nM for mAb 4C3-Fab; Dr. Sandra Smith-Gill
and Claudia Lipschultz, personal communication), while still
providing a window of antibody binding activity (OD 405 nm=1–
2). The concentrations of biotinylated antibodies were 4 nM and
21 nM for mAb 7C11 (1:500,000) and 4C3 (1:100,000),
respectively, and 53 nM for the polyclonal antibody (1:100,000).
Inhibition of IgE and monoclonal antibody binding by
epitope mutants
Inhibition ELISA were performed to compare the mutants of
the epitopes for mAb 7C11 and 4C3 for their capacity to inhibit
binding of the respective antibody to rBla g 2. In brief, mutants
and rBla g 2-N93Q were preincubated in tubes for 1 h at 4uC with
biotin-labeled mAb (at 1:5000 dilution; 580 nM and 428 nM for
biotinylated mAb 7C11 and 4C3, respectively) or IgE antibodies
(sera pool diluted 1:2) and then added to microtiter plates coated
with 10 mg/ml rBla g 2-N93Q. After 1 h (3 h for IgE antibodies)
incubation, plates were washed and incubated for 30 min with
streptavidin-peroxidase, and developed as above. The allergens
selected for testing inhibition of IgE antibody binding to rBla g 2-
N93Q were: Bla g 2-N93Q, Bla g 2-N268Q, natural Bla g 2,
K65A, D68aA, K132A, E233R, E233R-I199, E233R-I199-
N268Q and K251A.
Multiplex fluorescent array
Monoclonal antibodies 7C11 and 4C3 (20 mg) were coupled to
two different Luminex carboxylated fluorescent microsphere
bead sets (Luminex Corp., Austin, TX) and the multiplex
fluorescent array was performed as described [22,23]. The
mAb coupled beads were added along with rBla g 2-N93Q or
mutants at a concentration of 400 ng/ml. The mutants of the
epitope for the mAb 7C11 were tested using beads coated with
the mAb 4C3, and vice versa. Sera (1:5 dilution) or anti-Bla g 2
rabbit pAb (1:1,000 dilution) were added to wells, mixed with
beads, and incubated. The concentration of IgE in sera is in nM
range and was diluted further for the assay. Biotin labeled goat
anti-human IgE (KPL, Gaithersburg, MD) or biotin labeled goat
anti-rabbit IgG (Jackson ImmunoResearch, West Grove, PA),
both at 1:1000 dilution, were added to the wells that had been
incubated with sera or anti-Bla g 2 rabbit pAb, respectively.
Biotinylated mAbs were added to the wells where a mAb
sandwich assay was performed. In the final step, streptavidin-
phycoerythrin (4 mg/ml) was added to all wells and mixed.
Absorbance was measured in a Bio-Plex fluorescent suspension
array reader (Bio-Rad Laboratories, Hercules, CA). Each mutant
was compared to rBla g 2-N93Q by paired, Student t-test. P
values lower than 0.05 were considered significant.
Results
Inhibition of IgE antibody binding by mAb 7C11
Increasing concentrations of mAb 7C11 (from 0.001 to 10 mg/ml)
showed dose dependent inhibition of IgE antibody binding of up to
40% (Figure 1). Additional 3 sera showed an average inhibition of
25%. The rabbit anti-Bla g 2 polyclonal antibody showed inhibition
of IgE antibody binding of up to 82%. Background inhibition of IgE
antibody binding by mAb 4C1 against mite-allergen Der p 1 was
observedbelow 7%at100 mg/ml (data notshown). Inhibition of IgE
antibody binding by mAb 4C3 was previously reported [17].
Comparison of IgE antibody binding to Bla g 2 presented
by either 7C11 or 4C3 monoclonal antibodies
IgE and rabbit polyclonal antibody binding to Bla g 2 presented
by mAb 7C11 or 4C3 was compared using mAb coupled
microspheres in a multiplex array. A monomeric Bla g 2 mutant
was used as the capture allergen to avoid the possible influence of
Figure 1. Overlap of 7C11 mAb and IgE antibody epitopes. Inhibition of IgE antibody binding to Bla g 2 by mAb 7C11 (0.001–10 mg/ml) and a
rabbit anti-Bla g 2 polyclonal antibody.
doi:10.1371/journal.pone.0022223.g001
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[16]. The amino acid substitutions in the monomeric mutant do
not involve residues from the mAb epitopes and thus do not
prevent binding of both mAbs.
Polyclonal anti-Bla g 2 antibody binding to the allergen
monomer was very similar for the allergen presented by either
mAb 7C11 or 4C3 (Figure 2A). Forty nine sera from cockroach
allergic patients were tested and 19 sera with Median Fluorescence
Intensity Units (MFI).200 were chosen for further analysis. The
amount of IgE antibody bound to the allergen presented by either
mAb varied by 10-fold, from 200 to .3000 MFI (Figure 2B). In
general, similar amounts of IgE antibody were bound to rBla g 2
presented by either mAb 7C11 or 4C3 (ratios close to 1 in
Figure 2B), indicating that there was not an immunodominant
lobe of Bla g 2 for most patients.
Rational design of Bla g 2 epitope mutants based on
crystal structures of allergen-antibody complexes
The relevance of specific amino acids for 7C11 and 4C3 mAb
binding was investigated by site-directed mutagenesis of selected
residues in the epitopes identified by X-ray crystallography which
are located on the N and C-terminal lobes of Bla g 2, respectively
(Figure 3). They interact with complementarity determining
regions (CDRs) of the heavy (H1, H2, H3) and light (L1, L2,
L3) chains of the antibody [16,17]. Regarding the epitope for the
mAb 7C11, residues K65 and D68a were selected as part of the
longest loop which, together with R83, primarily interacts with the
light chain of the antibody (Figure 4A, in yellow). Residue D68a is
unique in the allergen since it interacts with both heavy and light
chains. Residues R83, E86 and K132 which interact with the
CDRs L3, H3 and H1/H2, respectively, were also mutated. E86,
as well as D100, maintain the orientation of the side chain of
R101-H3 by forming electrostatic interactions with this arginine,
which is also involved in multiple hydrophobic interactions with
I67 from the long loop of the epitope. K132 forms strong
hydrogen bonds with D52-H2 and additional contacts with
residues from H1. Three of the five residues selected for
mutagenesis (K65, R83 and K132) form cation-p interactions
with tyrosines 53-L2, 92-L3 and 33-H1 from the antibody
(Figure 4A).
In contrast to the epitope for the mAb 7C11, interactions of the
mAb 4C3 with the allergen involve carbohydrates and solvent
molecules (water and zinc), in addition to amino acids, and the
CDR L2 is not involved in the interaction [17]. Mutagenesis
aimed to disrupt two main anchoring sites of the mAb 4C3. One
site involves amino acids from three loops of the allergen (199–
202, the long loop 248–259 and 268–273) plus residues from the
C-terminal end of the helix 225–238. The most specific
interactions are between the positively charged R103 from CDR
H3 of the mAb 4C3 and the negatively charged C-terminal end of
the allergen helix 225–235, enhanced by the presence of a
negatively charged E233 (Figure 4B). Mutation of E233 to either a
neutral alanine or a positively charged arginine was aimed at
disrupting these charge-charge interactions. Residue I199 was also
mutated to the bulkier tryptophan in order to prevent the docking
of W105 from the CDR H3 into a hydrophobic pocket on Bla g 2
formed by A234, I199, and P256 (Figure 4B). Aspartate 248
interacts with metal (most likely Zn
2+) in one of the two observed
conformations and was mutated to alanine. This mutation aimed
to disrupt an extensive hydrogen bonded network formed by water
molecules and metal that mediates the remaining contacts between
CDRs L1 and L3 and two loops of the allergen (involving residues
248–252 and A234). Finally, lysine 251, which is the only residue
interacting directly with the CDRs L1 and L3 of the antibody
through Y32 (forming a cation-p interaction) and D92, respec-
tively, was mutated to alanine (Figure 4B).
Another anchoring site of mAb 4C3 is a carbohydrate at
position N268, whose trimannosyl core interacts with CDRs H1
and H2, plus N74 from the third loop of the heavy chain of the
antibody (usually not involved in recognition) (Figure 3). The
mutant N268Q was expressed alone to prevent glycosylation at
this site. In addition, mutants E233R and E233R-I199W were
expressed with and without N268Q to disrupt the interaction of
mAb 4C3 with amino acids and carbohydrates simultaneously. In
summary, this study is a mutagenesis analysis of the 7C11 mAb
epitope and an extension to our previously reported analysis of
Figure 2. Antibody binding to rBla g 2 presented by mAb 7C11 or 4C3 using multiplex array. A) Anti-Bla g 2 polyclonal antibody bound
to rBla g 2 (mean 6 standard deviation, n=5 experiments, p=0.059). B) IgE from sera of cockroach allergic patients bound to rBla g 2. The allergen
was presented by either mAb 7C11 (gray) or 4C3 (black). The first and second row of numbers under the X-axis are ratio of IgE bound to Bla g 2
presented by mAb 7C11 versus mAb 4C3 (100%) and serum number, respectively. MFI are Median Fluorescence Intensity Units.
doi:10.1371/journal.pone.0022223.g002
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substituting three amino acids on monoclonal antibody binding
[17].
Analysis of monoclonal antibody binding to the epitope
mutants
The overall folding of all the purified rBla g 2 mutants was
shown to be similar to the rBla g 2-N93Q. Purified rBla g 2-
N93Q and epitope mutants showed a main band at ,37 kDa
(monomer) and a minor band at ,74 kD (dimer) as expected on
SDS-PAGE, under non-reducing conditions [4]. Mutants of the
epitope for the mAb 7C11 were subjected to extensive quality
control by mass spectrometry and circular dichroism. The
mutations were confirmed by mass spectrometry. CD spectra of
the mutants of the epitope for the mAb 7C11, K65A, R83A,
E86A and K132A, were comparable to rBla g 2-N93Q and
natural Bla g 2, with minima between 205 and 215 nm and
maxima below 200 nm, indicating similar overall folding
(Figure 5). Only the D68aA CD spectrum displayed a higher b-
sheet content, as visualized by a negative shoulder between 220
Figure 3. Epitopes for mAb 7C11 and 4C3 are located on opposite lobes of Bla g 2. Ribbon diagram of rBla g 2 (gold) in complex with a Fab
fragment of the mAb 4C3 (blue) superimposed to the Fab9 of mAb 7C11 in complex with Bla g 2 (allergen not shown). Monoclonal Ab 7C11 binds to
the N-terminal lobe of the allergen and mAb 4C3 to the C-terminal lobe. Antibody fragments consist of a heavy and a light chain, in green and light
lilac for 7C11, and in marine blue and cyan for 4C3, respectively. The carbohydrates in position N268 are shown in red.
doi:10.1371/journal.pone.0022223.g003
Figure 4. Rational design for mutagenesis. A) Principal residues involved in the the mAb 7C11 epitope on the N-terminal lobe of Bla g 2. The
longest consecutive part of the epitope (shown in yellow) interacts with all three CDR of the light chain (surface in green) and has 9 residues (starting
at 60) from which two were mutated to alanine (K65 and D68a). K65, R83 and K132 form cation-p interactions with tyrosines Y53, Y92 and Y33 from
the mAb 7C11, respectively. The heavy chain of the antibody is shown in lilac. B) Main residues involved in the mAb 4C3 epitope on the C-terminal
lobe of Bla g 2. The surface of the allergen, with the main residues involved in antibody binding is shown in gold. The third loop of the heavy chain of
the antibody (in blue) includes: a) R103 attracted to the negatively charged E233, and b) W105 that docks into a hydrophobic pocked formed by
A234, I199 and P256 in Bla g 2. Residues K251 and Y32 involved in a cation-p interaction are also shown.
doi:10.1371/journal.pone.0022223.g004
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confirmed an overall proper folding of the mutants: when
presented by mAb coupled to microspheres, they showed similar
binding of a polyclonal Bla g 2-specific antibody, with parallel
dose-response curves (Figure 6A). These results indicated that the
mutated allergens had preserved conformational epitope(s)
required for mAb capture and for binding of polyclonal
antibodies, showing that they were overall properly folded.
Subsequently, the control for correct overall folding of mutated
allergens was performed by measuring binding of a Bla g 2-
specific polyclonal antibody to the mutants presented by the mAb
that binds to the lobe opposite to the mutation. Results showed
that the overall folding of the mutants of the epitope for the mAb
4C3 was also similar to rBla g 2-N93Q (Figure 6B). In contrast
with the mAb 7C11 epitope mutants, the dose-response curves
for certain mAb 4C3 epitope mutants were displaced to the right,
indicating an effect of these mutations (especially the N268Q
affecting glycosylation) on the polyclonal antibody binding
(Figure 6B).
Binding of the polyclonal antibody to recombinant Bla g 2
resulted in a wider window of absorbance compared to the natural
allergen (Figures 6A and B), whereas the same window was
obtained for natural and recombinant allergen with the two
combinations of mAb (Figure 6C and D). This could be explained
by the fact that the polyclonal antibody was raised against
recombinant Bla g 2, and although the natural and recombinant
allergens have similar CD spectra (Figure 5), differences in
epitopes recognized by the polyclonal antibody (maybe involving
different carbohydrates) could occur.
A) Monoclonal antibody binding to the mAb 7C11
epitope mutants
Parallel dose-response curves were obtained for natural Bla g 2,
rBla g 2-N93Q and the epitope mutants E86A, R83A and K65A.
The strongest effect on reduction of mAb 7C11 binding resulted
from the mutation K132A (Figure 6C). The three curves for E86A,
R83A and K65A were displaced to the right compared to rBla g 2-
N93Q, indicating a lower binding affinity of these mutants for
mAb 7C11, whereas the mutant D68aA lost its parallelism with
rBla g 2-N93Q.
In agreement with the dose-response curves by ELISA, and as
controls for the IgE antibody binding experiments performed by
multiplex array, a reduction of mAb 7C11 binding to four out of
five mutants of the epitope for the mAb 7C11 (K65A, D68aA,
R83A and K132A) presented by mAb 4C3 coupled to micro-
spheres was observed by multiplex technology, whereas the same
level of polyclonal antibody binding was obtained at these assay
conditions (data not shown). Lower levels of mAb binding to the
epitope mutants compared to rBla g 2-N93Q (except for E86) were
also observed in multiplex dose-response curves using 25 to
800 ng/ml of allergen, whereas the levels of bound anti-Bla g 2
polyclonal used as detection antibody were equivalent (data not
shown).
As a validation test, the dose-response curves and multiplex
array results were also compared to competition ELISA to
evaluate the ability of the mutants to compete with solid phase-
bound rBla g 2-N93Q for binding to the mAbs (Figure 7A). The
order of potency of the mutants for inhibiting mAb 7C11 binding
to Bla g 2 was: natural Bla g 2.Bla g 2-N93Q.R83A,E86A
.K65A.D68aA.K132A, in agreement with the relative binding
affinities obtained from the dose-response curves (Figure 6C). In
particular, mutant K132A did not inhibit binding of mAb 7C11 to
rBla g 2-N93Q at 10 mg/ml, dose at which the other mutants
showed significant or total levels of inhibition (Figure 7A). This
result shows an important loss in binding affinity of K132A for
mAb 7C11, in agreement with ELISA and multiplex results.
B) Monoclonal antibody binding to the mAb 4C3 epitope
mutants
The mutants of the epitope for the mAb 4C3 showed similar
binding to mAb 7C11 by ELISA, but had either similar or reduced
binding to mAb 4C3 compared to rBla g 2-N93Q. The strongest
effect on reduction of mAb 4C3 resulted from the mutations
K251A and E233R-I99W (with or without N268Q) (Figure 6D).
Dose-response curves showed a displacement to the right for most
of the mutations affecting the mAb 4C3 epitope, except for D248A
and E233R. The order of potency of the N93Q mutants for
inhibiting mAb 4C3 binding to Bla g 2 was: E233R.Bla g 2-
N93Q.E233R-I199W, similarly to the N268Q mutants: E233R-
N268Q.Bla g 2-N268Q.E233R-I199W-N268Q. Combination
Figure 5. CD spectra of natural Bla g 2 (black line) and rBla g 2-N93Q (gray dashed).
doi:10.1371/journal.pone.0022223.g005
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reducing mAb 4C3 (Figure 6D and 7B). ELISA dose-response
curves of the N268Q rBla g 2 mutants that lack carbohydrates at
that position were displaced to the right compared to the
equivalent allergens non mutated at position 268 (i.e. E233-
N268 and E233-I199-N268 versus E233 and E233-I199, respec-
tively) similarly to what was observed for the enzymatically
deglycosylated allergen [17]. Once the multiplex assays were
validated with all the mutants by ELISA dose-response curves and
inhibition assays, the IgE antibody binding assays were performed
by multiplex array technology in order to reduce the amount of
the sera used for the assays.
Analysis of IgE antibody binding to rBla g 2 mutants in a
fluorescent multiplex array assay
The effectsofmutationsonIgEantibody bindingvaried bypatient.
ThemutationsthatledtolowestIgEantibodybindingforcertainsera
were K65A, K132A, N268Q and E233R-I199W-N268Q (Figure 8).
There was no effect on IgE antibody binding for certain mutations
and some of the patients. The concentration of IgE in sera is in the
nMrange(i.e.estimated65 nMfortheserapool),andshouldbemost
likely low enough to allow changes in antibody binding to be
visualized.
Despite inter-patient differences, the reduction in the percent-
age of IgE bound to each mutant versus the rBla g 2-N93Q was
statistically significant for K65A, R83A, K132A, Bla g 2-N268Q,
K251A and E233R-I199W-N268Q. In inhibition assays using a
pool of six sera from patients highly sensitized to Bla g 2, the
mutants that had less capacity to inhibit IgE antibody binding to
rBla g 2 were E233R-199W-N268Q, followed by K251A (data not
shown).
Mutations K132A and K251A affected cation-p interactions
between allergen and antibody. The sum of percentage of decrease
in IgE antibody binding for the two mutants K132A and K251A
versus rBla g 2-N93Q ranged from 7 to 51% with an average of
25% (n=9 sera). The interaction between each lysine and the
Figure 6. Dose-response curves of Bla g 2 and epitope mutants by ELISA. A) Binding of the anti-Bla g 2 polyclonal antibody to mAb 7C11
epitope mutants. B) Binding of the anti-Bla g 2 polyclonal antibody to mAb 4C3 epitope mutants. C) Binding of mAb 7C11 to mAb 7C11 epitope
mutants, D) Binding of mAb 4C3 to mAb 4C3 epitope mutants. Data are mean 6 standard deviation of duplicates from one representative
experiment out of two performed for each panel. Legends in panels C and D also apply to panels A and B, respectively.
doi:10.1371/journal.pone.0022223.g006
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251 establish cation-p interactions with tyrosines that are
supported by a hydrogen bond with R50 from the heavy and
light chains of the antibodies 7C11 and 4C3, respectively. The two
lysine residues also interact with D52 and D92 from the heavy and
light chains of the antibodies, respectively.
Discussion
Bla g 2 is a major inhalant allergen associated with cockroach
sensitization and the development of asthma. We have previously
reported the crystal structures of Bla g 2 alone [7] and in complex
with Fab9 of the mAb 7C11 and Fab of the mAb 4C3 [16,17].
Both mAb inhibit IgE antibody binding up to 40–45%, as shown
here for 7C11 and previously for 4C3 [17]. Taking advantage of
the fact that both mAb bind to opposite lobes of Bla g 2, we
compared mAb and IgE antibody binding to mutants of the
epitopes presented by the mAb that binds on the opposite site of
the mutation. This experimental approach had the advantage of
analyzing antibody binding to non-fragmented allergen and
conformational epitopes. In contrast, most previous epitope
mapping studies reported patient differences in IgE antibody
epitope recognition by measuring antibody binding to fragments
or peptides of an allergen which have lost the structural
environment required for conformational epitopes [10,11].
A rational design of site-directed mutagenesis was performed
based on the three-dimensional structure of both mAb epitopes
[16,17]. Mutagenesis analysis showed that most of the amino acids
selected from different loops of the conformational epitopes were
contributing to the allergen-mAb interactions. Non effective
mutations either affected only one of the few interactions of the
allergen with a single residue of the antibody (E86), or an indirect
interaction through a metal ion (D248). The most important
residues were K132 for the mAb 7C11 epitope and I199 and K251
for the mAb 4C3 epitope. These mutations led to a) a displacement
to the right of dose-response curves compared to curves of allergens
with non-mutated epitope, and b) a decrease of the relative
inhibitory potency of the mutant for mAb binding to Bla g 2,
whereastheoverall foldingoftheallergenwaspreserved.Therefore,
thedecrease inantibody bindingcould be directly attributedtolocal
Figure 7. Inhibition of biotinylated mAb binding to rBla g 2 by allergen mutants using ELISA. A) Inhibition of binding of biotinylated-
mAb 7C11 to rBla g 2-N93Q by mAb 7C11 epitope mutants. B) Inhibition of binding of biotinylated-mAb 4C3 to rBla g 2-N93Q by mAb 4C3 epitope
mutants. Data are mean 6 standard deviation of duplicates from one representative experiment out of two performed for each panel.
doi:10.1371/journal.pone.0022223.g007
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overall structural alterations or breakdown of the molecule.
Interestingly, four of the effective mutations on mAb binding
(K65A, R83A, K132A, and K251A) disrupted cation-p interactions
and proved their importance for protein-protein recognition
[24,25]. The two most important ones (involving K132 and
K251) had a strikingly similar structural environment. The
relevance of lysine and positively charged amino acids in allergen-
IgE antibody interactions has previously been reported [26–30]. In
these studies, the rationale for selection of residues to mutate was
based on sequence or structural alignments, the identification of
solvent accessible residues (i.e. lysine in high amounts on the
allergen surface), or on epitopes previously identified by testing IgE
antibody bindingto syntheticpeptides correspondingto the allergen
sequence by immunoblotting or dot-spots [26–30]. In the present
study, the structural environment and mechanisms of allergen-mAb
interaction are revealed by a detailed analysis of the structure of
allergen-antibody complexes solved by X-ray crystallography.
Binding of mAb 4C3 to Bla g 2 was reduced by mutations
aimed at: a) the disruption of charge-charge interactions (E233A),
and, b) the disruption of antibody binding to a hydrophobic pocket
on Bla g 2 (I199W). The addition of the I199W substitution to the
E233R mutants further decreased antibody binding (as evidenced
by a displacement of the dose-response curves to the right) showing
the importance of the CDR3-H for the antibody interaction. This
region has been reported to be the most variable in length,
Figure 8. Binding of IgE antibodies from cockroach allergic patients to rBla g 2-N93Q and epitope mutants. A) IgE binding to mAb
7C11 epitope mutants, and B) IgE binding to mAb 4C3 epitope mutants. In A and B scatter plots show median of percentages (6 interquartile ranges)
of IgE binding versus rBla g 2-N93Q for the sera tested (n=8–11) Each data point was calculated as average of percentage of IgE binding (6 SEM)
versus the rBla g 2-N93Q for 1–4 tests per serum depending on serum availability.
doi:10.1371/journal.pone.0022223.g008
Figure 9. Structural environment of the lysine residues involved in cation-p interactions important for antibody binding. A) Lysine
132 interacting with the tyrosine 33 of the heavy chain of the mAb 7C11. B) Lysine 251 interacting with the tyrosine 32 of the light chain of the mAb
4C3.
doi:10.1371/journal.pone.0022223.g009
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ities [31,32].
Selected mutations from a rational design based on the crystal
structures of allergen-antibody complexes strongly affected the
binding of the mAb (K132A, K251A, E233R-I199W and E233R-
I199W-N268Q). However, such an important effect in reducing
antibody binding was not observed for IgE antibody binding, as
expected from mutating amino acids from only one of the multiple
epitopes involved in the IgE antibody response. Single substitu-
tions of lysines or arginines forming cation-p interactions resulted
in a decrease of IgE antibody binding. There was a tendency for a
stronger reduction of IgE antibody binding for mutants containing
the I199W substitution, as observed for monoclonal antibody
binding. These IgE antibody binding reductions are small but
detectable since other substitutions of similar residues (E, R, K) in
other parts of the molecular surface did not show this effect, with
medians of IgE antibody binding around 100% and narrower
interquartile ranges (between 98 and 111%) (data not shown).
Single point allergen mutants have previously been shown not to
lead to significant reduction of IgE reactivity [29,33]. These results
indicate that the IgE antibody response to Bla g 2 does not involve
a single immunodominant epitope. In contrast to a large number
of studies for mapping linear epitopes on allergens, only one
previous study followed a similar approach for indirectly
identifying IgE antibody binding sites on Bet v 1 using a murine
mAb that inhibits IgE antibody binding [34]. In this study, the Bet
v 1 residue E45 was reported to be critical for a major IgE
antibody binding epitope. Mutation of E45 to serine decreased IgE
antibody binding up to 60%, indicating that this epitope was
immunodominant, although not unique in the IgE antibody
repertoire [34].
We observed a contribution of sugars to the Bla g 2 interaction
with mAb 4C3 antibody by a displacement to the right of allergen
dose-response curves for the N268Q mutants (single substitution
or in combination with either E233R or E233R-I199W) versus the
equivalent allergen mutants glycosylated at this position 268. We
previously reported similar results with an enzymatically deglyco-
sylated rBla g 2 [17]. The 4C3 mAb epitope is a good model for
this analysis because, to the best of our knowledge, it is the only
epitope that involves interaction with both amino acids and
carbohydrates [17]. In this study, the contribution of carbohy-
drates on IgE antibody binding to Bla g 2 is shown as well.
Carbohydrates at position 268 appeared to be part of a ‘‘double
anchorage’’ of the IgE antibody, involving carbohydrates and
amino acids. First, removal of sugars by the N268Q substitution
resulted in a significant reduction of IgE antibody binding
compared to rBla g 2-N93Q. Second, a significant reduction of
the IgE antibody binding to the mutant E233R-I199A was only
observed when the N268Q substitution was also present. These
results indicate that disruption of the interaction by amino acid
substitution combined with removal of carbohydrate interfered
with the two anchorage sites for IgE. In summary, these results
further support the existence of common IgE epitopes among
cockroach allergic patients which overlap with mAb epitopes, and
prove the involvement of carbohydrates in IgE antibody binding
to Bla g 2. The importance of carbohydrates on IgE antibody
binding and their relevance on allergic disease is a matter of
debate. Cross-reactive carbohydrate determinants (CCD) from
plants and insects are N-glycans recognized by IgE, with minimal
or no clinical significance [35–37]. In contrast, recent data suggest
that IgE antibodies to mammalian carbohydrate epitopes can be
an important factor in anaphylaxis. Reactions to the mAb
cetuximab and delayed reactions to red meat are related to serum
IgE antibodies against oligosaccharide galactose-a-1,3-galactose
(alpha-gal), as a consequence of tick bites [38]. Although reduction
of IgE antibody binding to de-glycosylated allergens has been
previously reported, this study shows the mechanisms (kind of
interactions and residues) and the structural elements (trymanosyl
core of the N-glycans) involved in the interaction with mAb 4C3,
and how removal of carbohydrates at position 268 impairs IgE
antibody binding. Further studies on the effect of carbohydrates
attached to Bla g 2 at the T cell level and on the induction of
mediator-release are underway.
Interestingly, the relative importance of a mutated epitope
versus the remaining epitopes involved in the IgE response varied
by patient. For specific patients, the IgE antibody binding to some
of the mutants was reduced by 35–65%, indicating that the
mutated epitope was important for the allergic response of these
individual patients. These results are consistent with the fact that
the degree of IgE antibody binding inhibition by monoclonal
antibodies also varies depending on the sera. Similarly, small
percentages of patients (10–25%) with .50% reduction of IgE
antibody binding to specific single mutants has previously been
reported for Blo t 5 [29]. Differences in the decrease of antibody
binding by patient and mutation further supports heterogeneity in
the IgE antibody repertoire among allergic patients. Heterogeneity
in epitope recognition has also been observed for other allergens
[26,28,29,33].
Despite differences in IgE antibody binding by patient and per
mutation, the overall pattern of reduction of IgE antibody binding
was not random. Mutations that affected the binding of IgE
antibody to one patient also tended to reduce the binding for other
patients, while other mutations had little effect on antibody
binding. This is most obvious for the 7C11 mAb epitope mutants
K65A, R83A and K132A which showed a reduced binding of IgE
from most subjects (with the most pronounced effect for K132A),
whereas mutations D68aA and E86A did not show this effect. A
similar reduction of IgE antibody binding was also seen for the
4C3 mAb epitope mutants K251A and N268Q. The surface on
Bla g 2 covered by a mAb (893 A ˚ 2 in average) only represents
,6% of the total surface of the allergen (15,061 A ˚ 2). The relatively
larger reduction of binding of specific IgE for some sera caused by
a single or multiple amino acid change on the molecular surface of
Bla g 2 further emphasizes that the selected residues are important
for IgE antibody binding. Reduction in either affinity of IgE
antibody binding to a specific mutated epitope or in clonality (if
the binding to the epitope is abolished by the mutation) are
possible reasons for the reduction of IgE antibody binding
observed. These two properties of the IgE antibody repertoire,
affinity and clonality, have been reported to determine the effector
cell degranulation in response to allergen challenge [12]. The
interest of the study also relies on devising methods to reduce the
IgE binding capacity of allergens without disrupting their overall
structure, and to increase the knowledge of which residues in an
epitope can be mutated for the greatest effect on antibody binding.
In summary, the epitopes for mAb 7C11 and 4C3 are important
surface determinants overlapping with IgE antibody binding sites.
The epitope mapping approach involved a three-dimensional
analysis of epitopes whose structure had been solved by X-ray
crystallography. Therefore, mechanisms of allergen-antibody
interaction, including carbohydrates as part of the epitope or
cation-p interactions, could be elucidated. Key amino acids for
antibody binding were also identified, in contrast to previous
studies that predicted potential recognition sites according to
specific properties of amino acids from the allergen (their relevant
surface, electrostatic properties) and/or considering if these
properties were different in human homologues. This study is
part of a larger body of work to better understand conformational
Mechanisms of Antibody Binding to Bla g 2
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reduced IgE antibody binding. In addition, results provided insight
on the polyclonal IgE antibody response, regarding differences in
the IgE epitope repertoire among individuals. The possible
existence of immunodominant epitopes and the relative impor-
tance of IgE antibody binding sites were investigated. Overall, this
study demonstrates that the crystal structure of allergen-Ab
complexes can be used for detailed epitope mapping of
conformational epitopes, to identify the most important residues
for antibody binding and to elucidate mechanisms of allergen-
antibody interaction.
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